Clinical Trials Logo

Drug Interaction clinical trials

View clinical trials related to Drug Interaction.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT06428162 Active, not recruiting - Drug Abuse Clinical Trials

An Evaluation of Healthcare Providers' Adherence to Pharmacovigilance Practices in an African Community

Start date: February 18, 2024
Phase:
Study type: Observational

Egypt's several regions-rural, mixed, and urban-were given pre-designed surveys pertaining to drug adverse events and the role of pharmacovigilance in detection and reporting. The three sections of the survey were dedicated to studying health care professionals' knowledge concerning pharmacovigilance concepts and practices, as well as demographics and people reported or not reported. The survey also asked more questions regarding adverse occurrences that were reported.

NCT ID: NCT04590417 Active, not recruiting - Drug Interaction Clinical Trials

Assessment of Drug-drug Interactions Between Feminizing Hormone Therapy and Emtricitabine/Tenofovir Alafenamide Concomitantly for Pre-exposure Prophylaxis Among Transgender Women

Start date: October 1, 2020
Phase: N/A
Study type: Interventional

Recent studies have showed that there were significant drug-drug interactions (DDI) from feminizing hormone therapy (FHT) towards emtricitabine/tenofovir disoproxil fumarate (F/TDF)-based pre-exposure prophylaxis (PrEP) among transgender women (TGW). New strategies for PrEP among TGW who use FHT are urgently needed. Because tenofovir alafenamide (TAF) can achieve higher intracellular TFV-DP levels with lower tenofovir plasma concentrations, it is promising that both plasma TFV and intracellular TFV-DP levels might not be significantly affected by FHT. The current study aims to determine the pharmacokinetics DDI between FHT and F/TAF-based PrEP among TGW.